MRNA Overexpression is Associated with Worse Prognostic Factors in Papillary Thyroid Carcinoma

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2017 Feb 23

PMID 28223310

Citations 10

Authors

June Young Choi

Jin Wook Yi

Jun Hyup Lee

Ra-Yeong Song

Hyeongwon Yu

Hyungju Kwon

Young Jun Chai

Su-Jin Kim

Kyu Eun Lee

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to assess the relationship between vitamin D receptor gene () expression and prognostic factors in papillary thyroid cancer (PTC). mRNA sequencing and somatic mutation data from The Cancer Genome Atlas (TCGA) were analyzed. mRNA expression was compared to clinicopathologic variables by linear regression. Tree-based classification was applied to find cutoff and patients were split into low and high group. Logistic regression, Kaplan-Meier analysis, differentially expressed gene (DEG) test and pathway analysis were performed to assess the differences between two groups. mRNA expression was elevated in PTC than that in normal thyroid tissue. expressions were high in classic and tall-cell variant PTC and lateral neck node metastasis was present. High group was also associated with classic and tall cell subtype, AJCC stage IV and lower recurrence-free survival. DEG test reveals that 545 genes were upregulated in high group. Thyroid cancer-related pathways were enriched in high group in pathway analyses. mRNA overexpression was correlated with worse prognostic factors such as subtypes of papillary thyroid carcinoma that are known to be worse prognosis, lateral neck node metastasis, advanced stage and recurrence-free survival.

Citing Articles

VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.

Xia X, Xu F, Dai D, Xiong A, Sun R, Ling Y Biosci Rep. 2024; 44(5).

PMID: 38639057 PMC: 11065647. DOI: 10.1042/BSR20231845.

Uncovering key molecular mechanisms in the early and late-stage of papillary thyroid carcinoma using association rule mining algorithm.

Hosseiniyan Khatibi S, Zununi Vahed S, Homaei Rad H, Emdadi M, Akbarpour Z, Teshnehlab M PLoS One. 2023; 18(11):e0293335.

PMID: 37917782 PMC: 10621943. DOI: 10.1371/journal.pone.0293335.

Maciejewski A, Lacka K Int J Mol Sci. 2022; 23(21).

PMID: 36362448 PMC: 9658610. DOI: 10.3390/ijms232113661.

The Role of Vitamin D as a Prognostic Marker in Papillary Thyroid Cancer.

Bains A, Mur T, Wallace N, Noordzij J Cancers (Basel). 2021; 13(14).

PMID: 34298730 PMC: 8304998. DOI: 10.3390/cancers13143516.

Association of Vitamin D receptor gene variations with Gastric cancer risk in Kashmiri population.

Qadir J, Majid S, Khan M, Wani M Mol Biol Rep. 2021; 48(4):3313-3325.

PMID: 33942233 DOI: 10.1007/s11033-021-06376-z.

References

Krishnan A, Trump D, Johnson C, Feldman D . The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am. 2012; 38(1):161-78. PMC: 5731474. DOI: 10.1016/j.rdc.2012.03.014. View

Buras R, Schumaker L, Davoodi F, Brenner R, Shabahang M, Nauta R . Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat. 1994; 31(2-3):191-202. DOI: 10.1007/BF00666153. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Song M, Wu K, Chan A, Fuchs C, Giovannucci E . Plasma 25-hydroxyvitamin D and risk of colorectal cancer after adjusting for inflammatory markers. Cancer Epidemiol Biomarkers Prev. 2014; 23(10):2175-80. PMC: 4184943. DOI: 10.1158/1055-9965.EPI-14-0712. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Giovannucci E . Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol. 2008; 19(2):84-8. DOI: 10.1016/j.annepidem.2007.12.002. View

Ma Y, Yu W, Hershberger P, Flynn G, Kong R, Trump D . 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther. 2008; 7(9):3047-55. PMC: 2587026. DOI: 10.1158/1535-7163.MCT-08-0243. View

Clinckspoor I, Hauben E, Verlinden L, Van den Bruel A, Vanwalleghem L, Vander Poorten V . Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem. 2012; 60(7):502-11. PMC: 3460353. DOI: 10.1369/0022155412447296. View

10.

Guo Y, Xiao P, Lei S, Deng F, Xiao G, Liu Y . How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai). 2008; 40(5):426-36. DOI: 10.1111/j.1745-7270.2008.00418.x. View

11.

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

12.

Izkhakov E, Somjen D, Sharon O, Knoll E, Aizic A, Fliss D . Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma. J Steroid Biochem Mol Biol. 2016; 159:26-30. DOI: 10.1016/j.jsbmb.2016.02.016. View

13.

Sharma V, Fretwell D, Crees Z, Kerege A, Klopper J . Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism. Thyroid. 2010; 20(10):1103-11. PMC: 2958447. DOI: 10.1089/thy.2010.0096. View

14.

Zehnder D, Bland R, Williams M, McNinch R, Howie A, Stewart P . Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001; 86(2):888-94. DOI: 10.1210/jcem.86.2.7220. View

15.

Kostner K, Denzer N, Muller C, Klein R, Tilgen W, Reichrath J . The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009; 29(9):3511-36. View

16.

Deeb K, Trump D, Johnson C . Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7(9):684-700. DOI: 10.1038/nrc2196. View

17.

Colston K, Berger U, Coombes R . Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989; 1(8631):188-91. DOI: 10.1016/s0140-6736(89)91204-x. View

18.

Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342-57. DOI: 10.1038/nrc3691. View

19.

Ali M, Vaidya V . Vitamin D and cancer. J Cancer Res Ther. 2008; 3(4):225-30. DOI: 10.4103/0973-1482.38998. View

20.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View